Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stephania longa + Jiezai rice with sintilimab in second-line PD-L1-positive NSCLC
ChiCTR2500114858Phase 2Recruiting
- Sponsor
- Hainan General Hospital
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and Stephania longa in non-small cell lung cancer (NSCLC), sponsored by Hainan General Hospital. Primary endpoint: Progression Free Survival. Started Dec 2025; status: recruiting.
02
Drugs
sintilimabStephania longa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500114858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114858.